

Supplementary Table 1

Cell line	Histology	Genomic profile	EGFR Normalized MFI (% of positive cells)	PD-L1 Normalized MFI (% of positive cells)	MHC-I Normalized MFI (% of positive cells)
H460	Adenocarcinoma	KRAS (Gln61His) STK11 (Gln37Ter) PIK3CA (Glu545Lys)	80 (75%)	90 (85%)	10 (7%)
A549	Adenocarcinoma	KRAS (Gly12Ser) STK11 (Gln37Ter)	30 (55%)	65 (94%)	20 (23%)
H1299	Adenocarcinoma	TP53 del NRAS (missense)	80 (90%)	90 (85%)	5 (3%)
PC9	Adenocarcinoma	EGFR (Glu746_Ala750del)	70 (99%)	60 (80%)	30 (78%)
H1975	Adenocarcinoma	EGFR (Thr790Met and Leu858Arg) TP53 (Arg273His)	80 (98%)	50 (68%)	20 (21%)
HCC827	Adenocarcinoma	EGFR (Glu746_Ala750del)	85 (100%)	60 (84%)	40 (28%)
H441	Adenocarcinoma	KRAS (Gly12Val)	75 (80%)	70 (73%)	40 (50%)
CALU-3	Adenocarcinoma	TP53 (Met237Ile)	80 (90%)	30 (35%)	30 (25%)
Calu1	Squamous carcinoma	KRAS (Gly12Cys)	100 (95%)	90 (95%)	40 (50%)
H157	Squamous carcinoma	KRAS (Gly12Arg) TP53 (Arg306Ter)	90 (99%)	70 (80%)	30 (35%)
HCC95	Squamous carcinoma	Wild Type	10 (15%)	40 (45%)	20 (25%)
H82	Small cell carcinoma	TP53 (Thr125Thr)	8 (11%)	50 (65%)	10 (15%)
H69	Small cell carcinoma	PIK3CA (Gly106_Arg108del) RB1(Glu748Ter) TP53 (Glu171Ter)	12 (20%)	30 (35%)	20 (30%)

Flow cytometric analysis for EGFR, PD-L1 and MHC-I expression on a panel of lung cancer cell lines, including adenocarcinoma, squamous carcinoma and small cell carcinoma cells. Normalized mean fluorescence intensities (MFI) values are presented along with % of positive cells.